H Rudzki

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 642 citations

Medicine, Pharmacology, Pharmacotherapy +16

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

Hiddo J.L. Heerspink, C. David Sjöström, Niels Jongs et al. · European Heart Journal · 2021 · 122 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

Hiddo J.L. Heerspink, David Z.I. Cherney, Douwe Postmus et al. · Kidney International · 2021 · 94 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Nephropathy of type II diabetes: Evidence for hereditary factors?

Krzysztof Strojek, W Grzeszczak, E. Morawin et al. · Kidney International · 1997 · 60 citations · Full text

Medicine, Endocrinology, Nephrology +14

[Clinical assessment of treatment results for atherosclerotic ischemia of the lower extremities with intraarterial ozone injections].

J Sroczyński, Z Antoszewski, B Matyszczyk et al. · PubMed · 1993 · 10 citations

Medicine, Pharmacotherapy, Surgery +13